REGN
- Regeneron Pharmaceuticals, Inc.
()
Overview
Company Summary
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of serious medical conditions. The company utilizes advanced technologies in genetics, human genetics, and functional genomics to identify potential targets for drug development.
Regeneron's core competency lies in its expertise in monoclonal antibody (mAb) technology. Monoclonal antibodies are engineered molecules that can specifically target and bind to certain proteins or cells in the body, influencing their activity. These antibodies can be manipulated and optimized to create therapeutic drugs with various applications.
The company has developed several successful medications through its research and development pipeline. One of its most notable achievements is EYLEA� (aflibercept) Injection, which is used to treat multiple eye conditions, including wet age-related macular degeneration and diabetic macular edema. EYLEA� has been widely prescribed and has significantly improved the quality of life for many patients.
Additionally, Regeneron has collaborated with other pharmaceutical companies, including Sanofi, to develop and market drugs. Their most notable joint venture is the development and manufacturing of antibody treatments, including Kevzara� (sarilumab) and Dupixent� (dupilumab). These drugs are used to treat conditions such as rheumatoid arthritis and atopic dermatitis, respectively.
Regeneron's research and development efforts extend beyond ophthalmology and immunology. The company is actively involved in researching potential therapies for diseases like cancer, cardiovascular diseases, inflammatory diseases, and neurologic conditions.
In summary, Regeneron Pharmaceuticals, Inc. is a biotechnology company that leverages its expertise in genetics and monoclonal antibody technology to discover, develop, and commercialize innovative medicines for various medical conditions.